{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T21:21:15Z","timestamp":1771190475740,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12094-021-02598-6","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T12:02:34Z","timestamp":1618920154000},"page":"1885-1904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-8362","authenticated-orcid":false,"given":"N. N.","family":"Alrabadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Abushukair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. E.","family":"Ababneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. S.","family":"Syaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. S.","family":"Al-Horani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Qarqash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. A.","family":"Darabseh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Al-Sous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R.","family":"Al-Aomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.. B.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. A.","family":"Al Qarqaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"2598_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2598_CR2","first-page":"1","volume":"50","author":"recent progress and potential biomarkers","year":"2018","unstructured":"recent progress and potential biomarkers. Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors. Exp Mol Med. 2018;50:1\u201311.","journal-title":"Exp Mol Med"},{"key":"2598_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"2598_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"2598_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/jcm8030368","volume":"8","author":"S Wr\u00f3bel","year":"2019","unstructured":"Wr\u00f3bel S, Przyby\u0142o M, St\u0119pie\u0144 E. The clinical trial landscape for melanoma therapies. J Clin Med. 2019;8:368.","journal-title":"J. Clin. Med."},{"key":"2598_CR6","first-page":"39","volume":"37","author":"Opdivo-Yervoy Combination Approved for Melanoma","year":"2015","unstructured":"Opdivo-Yervoy Combination Approved for Melanoma. First Combination-Immunotherapy Regimen for Cancer. Oncol Times. 2015;37:39.","journal-title":"Oncol. Times"},{"key":"2598_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069\u201386.","journal-title":"Cancer Discov"},{"key":"2598_CR8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239\u201351.","journal-title":"Lancet Oncol"},{"key":"2598_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"key":"2598_CR10","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24:1260\u201370.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2598_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11912-020-0894-z","volume":"22","author":"NA Babacan","year":"2020","unstructured":"Babacan NA, Eroglu Z. Treatment options for advanced melanoma after anti-PD-1 therapy. Curr Oncol Rep. 2020;22:38.","journal-title":"Curr Oncol Rep"},{"key":"2598_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (London, England). 2014;384:1109\u201317.","journal-title":"Lancet (London, England)"},{"key":"2598_CR13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet (London, England). 2017;390:1853\u201362.","journal-title":"Lancet (London, England)"},{"key":"2598_CR14","unstructured":"Network, N. C. C. Cutaneous Melanoma (Version 4.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma_blocks.pdf (2020)."},{"key":"2598_CR15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"2598_CR16","unstructured":"GA Wells, B Shea, D O\u2019Connell, J Peterson, V Welch, M Losos, P. T. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"2598_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"key":"2598_CR18","doi-asserted-by":"publisher","first-page":"20170457","DOI":"10.1259\/bjr.20170457","volume":"91","author":"B Somarouthu","year":"2018","unstructured":"Somarouthu B, et al. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol. 2018;91:20170457.","journal-title":"Br J Radiol"},{"key":"2598_CR19","unstructured":"Institute, N. C. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf (2017)."},{"key":"2598_CR20","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890.","journal-title":"BMJ"},{"key":"2598_CR21","unstructured":"Team, R. C. R: A Language and Environment for Statistical Computing. (2013)."},{"key":"2598_CR22","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"2598_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/JCO.19.01464","volume":"38","author":"A Betof Warner","year":"2020","unstructured":"Betof Warner A, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1655\u201363.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2598_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","volume":"75","author":"L Zimmer","year":"2017","unstructured":"Zimmer L, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017;75:47\u201355.","journal-title":"Eur J Cancer"},{"key":"2598_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/bjc.2016.107","volume":"114","author":"S Bowyer","year":"2016","unstructured":"Bowyer S, et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer. 2016;114:1084\u20139.","journal-title":"Br J Cancer"},{"key":"2598_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.advms.2020.05.005","volume":"65","author":"B Cybulska-Stopa","year":"2020","unstructured":"Cybulska-Stopa B, et al. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients\u2014real world evidence. Adv Med Sci. 2020;65:316\u201323.","journal-title":"Adv Med Sci"},{"key":"2598_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/1346-8138.15073","volume":"46","author":"A Tsutsumida","year":"2019","unstructured":"Tsutsumida A, et al. Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma. J Dermatol. 2019;46:947\u201355.","journal-title":"J Dermatol"},{"key":"2598_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.10.009","volume":"89","author":"Y Fujisawa","year":"2018","unstructured":"Fujisawa Y, et al. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients. J Dermatol Sci. 2018;89:60\u20136.","journal-title":"J Dermatol Sci"},{"key":"2598_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/1346-8138.14865","volume":"46","author":"Y Muto","year":"2019","unstructured":"Muto Y, et al. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. J Dermatol. 2019;46:498\u2013506.","journal-title":"J Dermatol"},{"key":"2598_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220924719","author":"K Baron","year":"2020","unstructured":"Baron K, et al. Comparative effectiveness of second-line ipilimumab vs nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2020. https:\/\/doi.org\/10.1177\/1078155220924719.","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol. Pharm. Pract."},{"key":"2598_CR31","doi-asserted-by":"publisher","first-page":"e21552","DOI":"10.1200\/JCO.2018.36.15_suppl.e21552","volume":"36","author":"I Mehmi","year":"2018","unstructured":"Mehmi I, Hill J. Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma. J Clin Oncol. 2018;36:e21552\u2013e21552.","journal-title":"J Clin Oncol"},{"key":"2598_CR32","doi-asserted-by":"publisher","first-page":"P126","DOI":"10.1186\/2051-1426-3-S2-P126","volume":"3","author":"P Prithviraj","year":"2015","unstructured":"Prithviraj P, et al. Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy. J Immunother Cancer. 2015;3:P126\u2013P126.","journal-title":"J Immunother Cancer"},{"key":"2598_CR33","doi-asserted-by":"publisher","first-page":"9505","DOI":"10.1200\/JCO.2019.37.15_suppl.9505","volume":"37","author":"M Weichenthal","year":"2019","unstructured":"Weichenthal M, et al. Salvage therapy after failure from anti-PD-1 single agent treatment: a Study by the German ADOReg melanoma registry. J Clin Oncol. 2019;37:9505.","journal-title":"J Clin Oncol"},{"key":"2598_CR34","doi-asserted-by":"publisher","first-page":"9514","DOI":"10.1200\/JCO.2018.36.15_suppl.9514","volume":"36","author":"D Olson","year":"2018","unstructured":"Olson D, et al. Phase II trial of pembrolizumab (pembro) plus 1 mg\/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel). J Clin Oncol. 2018;36:9514.","journal-title":"J Clin Oncol"},{"key":"2598_CR35","unstructured":"Long, G. V. et al. Outcomes in patients (pts) treated with ipilimumab (ipi) after pembrolizumab (pembro) in KEYNOTE-006. in Society of Melanoma Research 2016 Congress. (2016)."},{"key":"2598_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","volume":"19","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2018;19:229\u201339.","journal-title":"Lancet Oncol"},{"key":"2598_CR37","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392.","journal-title":"Lancet Oncol"},{"key":"2598_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.bulcan.2019.04.010","volume":"106","author":"X Mignard","year":"2019","unstructured":"Mignard X, et al. Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer? Bull Cancer. 2019;106:725\u201333.","journal-title":"Bull Cancer"},{"key":"2598_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.36469\/jheor.2020.12853","volume":"7","author":"M Tahara","year":"2020","unstructured":"Tahara M, et al. Re-challenge of platinum-based chemotherapy for platinum-refractory patients with recurrent or metastatic head and neck cancer: claims data analysis in Japan. J Heal Econ outcomes Res. 2020;7:43\u201351.","journal-title":"J Heal Econ outcomes Res"},{"key":"2598_CR40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10637-016-0373-4","volume":"34","author":"J Cho","year":"2016","unstructured":"Cho J, et al. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Invest New Drugs. 2016;34:677\u201384.","journal-title":"Invest New Drugs"},{"key":"2598_CR41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","volume":"35","author":"SP D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo SP, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:226\u201335.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2598_CR42","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cam4.2110","volume":"8","author":"Y Fujisawa","year":"2019","unstructured":"Fujisawa Y, et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med. 2019;8:2146\u201356.","journal-title":"Cancer Med"},{"key":"2598_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/CMR.0000000000000197","volume":"25","author":"J Thierauf","year":"2015","unstructured":"Thierauf J, et al. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res. 2015;25:503\u20139.","journal-title":"Melanoma Res"},{"key":"2598_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13643-019-1082-9","volume":"8","author":"B Duyx","year":"2019","unstructured":"Duyx B, Swaen GMH, Urlings MJE, Bouter LM, Zeegers MP. The strong focus on positive results in abstracts may cause bias in systematic reviews: a case study on abstract reporting bias. Syst Rev. 2019;8:174.","journal-title":"Syst Rev"},{"key":"2598_CR45","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"2598_CR46","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1510\u20137.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2598_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2020.07.009","author":"E Gobbini","year":"2020","unstructured":"Gobbini E, et al. Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients. Bull Cancer. 2020. https:\/\/doi.org\/10.1016\/j.bulcan.2020.07.009.","journal-title":"Bull Cancer"},{"key":"2598_CR48","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3167\u201375.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2598_CR49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2018.12.034","volume":"176","author":"M Sade-Feldman","year":"2019","unstructured":"Sade-Feldman M, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019;176:404.","journal-title":"Cell"},{"key":"2598_CR50","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8:1136.","journal-title":"Nat Commun"},{"key":"2598_CR51","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u201329.","journal-title":"N Engl J Med"},{"key":"2598_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/164_2017_11","volume-title":"pp 109\u2013128","author":"RN Ramos","year":"2018","unstructured":"Ramos RN, Piaggio E, Romano E. Mechanisms of resistance to immune checkpoint antibodies BT\u2014mechanisms of drug resistance in cancer therapy. In: Mandal\u00e0 M, Romano E, editors. pp 109\u2013128. New York: Springer; 2018. https:\/\/doi.org\/10.1007\/164_2017_11."},{"key":"2598_CR53","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","volume":"25","author":"D Chowell","year":"2019","unstructured":"Chowell D, et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019;25:1715\u201320.","journal-title":"Nat Med"},{"key":"2598_CR54","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion M, et al. Somatic HLA class I Loss Is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 2021;11:282\u201392.","journal-title":"Cancer Discov"},{"key":"2598_CR55","doi-asserted-by":"publisher","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","volume":"8","author":"J Haanen","year":"2020","unstructured":"Haanen J, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer. 2020;8:e000604.","journal-title":"J Immunother Cancer"},{"key":"2598_CR56","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:250\u20135.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2598_CR57","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721\u20138.","journal-title":"JAMA Oncol"},{"key":"2598_CR58","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 2019;5:1310\u20137.","journal-title":"JAMA Oncol"},{"key":"2598_CR59","first-page":"429","volume":"18","author":"R Reschke","year":"2020","unstructured":"Reschke R, Ziemer M. Rechallenge with checkpoint inhibitors in metastatic melanoma. JDDG J der Dtsch Dermatologischen Gesellschaft. 2020;18:429\u201336.","journal-title":"JDDG J der Dtsch Dermatologischen Gesellschaft"},{"key":"2598_CR60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1634\/theoncologist.2016-0189","volume":"22","author":"B Herzberg","year":"2017","unstructured":"Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 2017;22:81\u20138.","journal-title":"Oncologist"},{"key":"2598_CR61","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1756287215597647","volume":"7","author":"M Weinstock","year":"2015","unstructured":"Weinstock M, McDermott D. Targeting PD-1\/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2015;7:365\u201377.","journal-title":"Ther Adv Urol"},{"key":"2598_CR62","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1111\/1759-7714.13502","volume":"11","author":"M Sternschuss","year":"2020","unstructured":"Sternschuss M, et al. Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1\/PD-L1 agents? Thorac cancer. 2020;11:2331\u20134.","journal-title":"Thorac cancer"},{"key":"2598_CR63","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkmate 025. Eur Urol. 2017;72:368\u201376.","journal-title":"Eur Urol"},{"key":"2598_CR64","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/1759-7714.13483","volume":"11","author":"S Kitagawa","year":"2020","unstructured":"Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020;11:1927\u201333.","journal-title":"Thorac Cancer"},{"key":"2598_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/CJI.0000000000000148","volume":"40","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, et al. Sequencing treatment in BRAFV600 mutant melanoma: anti-PD-1 before and after BRAF inhibition. J Immunother. 2017;40:31\u20135.","journal-title":"J Immunother"},{"key":"2598_CR66","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","volume":"30","author":"U Dafni","year":"2019","unstructured":"Dafni U, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:1902\u201313.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2598_CR67","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","volume":"30","author":"J Vera Aguilera","year":"2020","unstructured":"Vera Aguilera J, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30:364\u201375.","journal-title":"Melanoma Res."},{"key":"2598_CR68","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fonc.2020.00070","volume":"10","author":"R Hadash-Bengad","year":"2020","unstructured":"Hadash-Bengad R, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma\u2014a retrospective study. Front Oncol. 2020;10:70.","journal-title":"Front Oncol"},{"key":"2598_CR69","first-page":"106","volume":"13","author":"SE Park","year":"2018","unstructured":"Park SE, et al. Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 Inhibitors in patients with non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13:106\u201311.","journal-title":"J. Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"2598_CR70","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","volume":"121","author":"K Saleh","year":"2019","unstructured":"Saleh K, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2019;121:123\u20139.","journal-title":"Eur J Cancer"},{"key":"2598_CR71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15\u201325.","journal-title":"Cell Death Differ"},{"key":"2598_CR72","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1658\u201367.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2598_CR73","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","volume":"35","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy. J Clin Oncol. 2017;35:9520.","journal-title":"J Clin Oncol"},{"key":"2598_CR74","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1889\u201394.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02598-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02598-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02598-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T12:27:24Z","timestamp":1627129644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02598-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2598"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02598-6","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This is a systematic review and meta-analysis article which doesn\u2019t need informed consent or any ethical approvals in its current form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}